Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF) derivatives as potential anticancer agents.

ID: ALA4765458

Journal: Eur J Med Chem

Title: Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF) derivatives as potential anticancer agents.

Authors: He X,Zhong M,Li S,Li X,Li Y,Li Z,Gao Y,Ding F,Wen D,Lei Y,Zhang Y

Abstract: A series of organoselenium compounds based on the hybridization of nonsteroidal antiinflammatory drugs (NSAIDs) scaffolds and Se functionalities (-SeCN and -SeCF) were synthesized and characterized, and evaluated against four types of cancer cell lines, SW480 (human colon adenocarcinoma cells), HeLa (human cervical cancer cells), A549 (human lung carcinoma cells), MCF-7 (human breast adenocarcinoma cells). Interestingly, most of the investigated compounds showed active in reducing the viability of different cancer cell lines. The most active compound 3h showed IC values lower than 20 μM against the four cancer cell lines, particularly to SW480 and MCF-7 with IC 50 values of 4.9 and 3.4 μM, respectively. Furthermore, NSAIDs-SeCN derivatives (2h and 2i) and NSAIDs-SeCF derivatives (3h and 3i) were selected to investigate their ability to induce apoptosis in MCF-7 cells via modulation the expression of anti-apoptotic Bcl-2 protein, pro-inflammatory cytokines (IL-2) and proapoptotic caspase-3 protein. Moreover, the redox properties of the synthesized organoselenium candidates were conducted by 2, 2-didiphenyl-1-picrylhydrazyl (DPPH), bleomycin dependent DNA damage and glutathione peroxidase (GPx)-like assays. Taken together, these NSAIDs-Se candidates could provide promising new lead derivatives for further potential anticancer drug development.

CiteXplore: 32987314

DOI: 10.1016/j.ejmech.2020.112864

Patent ID: ┄